Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.
Interview with Marilyn Matz, CEO and Co-founder at Paradigm4, and 2020 NACD Directorship 100™ honoree, and her colleague Dr. Zachary Pitluk, VP of Life Sciences and Health Care at Paradigm4. Founded by renowned database researcher, Turing Award laureate MIT Professor Michael Stonebraker, Paradigm4 is not just any data analytics company
The idea of precision medicine – delivering the right drug treatment to the right patient at the right time and at the right dose – underpins current thinking in pharma R&D. by Zach Pitluk
Addressing the vital economic challenge of uncovering new critical quality attributes (CQAs), Paradigm4’s REVEALTM Analytical Development app enables data analysts…
